abt-126
Small moleculeexperimental
Clinical trial activity
14 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
9
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2009 (NCT00867399)
Timeline
Indications
Mechanism of action
CHRNA7 agonist
Alpha-7 nicotinic receptor: consists entirely of a7 subunits (pentamere) CNS-type.
Chemistry & pharmacology
Loading structure…
SMILES
c1ccc(-c2nnc(O[C@@H]3C4CC5C[C@H]3CN(C5)C4)s2)cc1- Mol. weight
- 313.43 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545231 ↗
Also known as
- abt-126
- abt-126
- abt-126
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01834638 | Phase 2 | Mar 1, 2013 | AbbVie |
| NCT01690195 | Phase 2 | Sep 1, 2012 | AbbVie |
| NCT01678755 | Phase 2 | Aug 1, 2012 | AbbVie |
| NCT01676935 | Phase 2 | Aug 1, 2012 | AbbVie |
| NCT01655680 | Phase 2 | May 1, 2012 | AbbVie |
| NCT01549834 | Phase 2 | Mar 1, 2012 | AbbVie |
| NCT01527916 | Phase 2 | Feb 1, 2012 | AbbVie |
| NCT01482845 | Phase 1 | Nov 1, 2011 | Abbott |
| NCT01095562 | Phase 2 | Mar 1, 2010 | AbbVie |
| NCT01043458 | Phase 1 | Nov 1, 2009 | Abbott |
| NCT00948909 | Phase 2 | Oct 1, 2009 | AbbVie |
| NCT00959634 | Phase 1 | Aug 1, 2009 | Abbott |
| NCT00912431 | Phase 1 | Jun 1, 2009 | Abbott |
| NCT00867399 | Phase 1 | Mar 1, 2009 | Abbott |
Showing 14 of 14 trials
Page 1 / 1